1816 related articles for article (PubMed ID: 33025047)
1. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
Front Immunol; 2021; 12():782775. PubMed ID: 34790207
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
7. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
8. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
Front Immunol; 2021; 12():628906. PubMed ID: 33777013
[TBL] [Abstract][Full Text] [Related]
9. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
10. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment.
Hung LVM; Ngo HT; Van Pham P
Adv Exp Med Biol; 2020; 1292():113-130. PubMed ID: 32430854
[TBL] [Abstract][Full Text] [Related]
12. CAR-T cell therapy for lung cancer: Potential and perspective.
Chen L; Chen F; Li J; Pu Y; Yang C; Wang Y; Lei Y; Huang Y
Thorac Cancer; 2022 Apr; 13(7):889-899. PubMed ID: 35289077
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
14. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.
Li H; Huang Y; Jiang DQ; Cui LZ; He Z; Wang C; Zhang ZW; Zhu HL; Ding YM; Li LF; Li Q; Jin HJ; Qian QJ
Cell Death Dis; 2018 Feb; 9(2):177. PubMed ID: 29415996
[TBL] [Abstract][Full Text] [Related]
16. Next-generation CAR T cells to overcome current drawbacks.
Lundh S; Maji S; Melenhorst JJ
Int J Hematol; 2021 Nov; 114(5):532-543. PubMed ID: 32594314
[TBL] [Abstract][Full Text] [Related]
17. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
18. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
[TBL] [Abstract][Full Text] [Related]
19. [CAR-T Immunotherapy and Non-small Cell Lung Cancer: Bottleneck and Dawn].
Zhang L; Li H; Zhang F; Wang S; Li G
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):916-920. PubMed ID: 32810975
[TBL] [Abstract][Full Text] [Related]
20. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]